Core Insights - Obagi Medical has selected Schweiger Dermatology as a key partner for its Aesthetics Leadership with the Hyaluronic Acid (ALOHA) Program, emphasizing clinical excellence and rapid access to care [1] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare and aesthetic solutions, with over 35 years of experience in the industry [7] - Schweiger Dermatology is a prominent national dermatology practice that offers a range of services including medical, cosmetic, and surgical dermatology, focusing on high-quality, personalized care [8] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [9] Partnership Details - The partnership will generate real-world data to translate clinical safety and efficacy from FDA pivotal trials into everyday practice [2] - The ALOHA Program includes a Phase 4 clinical study and a real-world evaluation program to enhance patient satisfaction and provider-patient relationships [3] - Initial program activities are expected to commence in early 2026, with findings to be presented at internal leadership meetings and key industry conferences [4] Product Information - Obagi saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, aiming for natural-looking results and high performance [5]

Core Insights - Obagi Medical has selected It's a Secret Med Spa as a premier luxury partner for its ALOHA Program, focusing on translating clinical safety and efficacy into real-world applications [1][3] - The partnership aims to enhance patient satisfaction and strengthen provider-client relationships through hands-on experience with Obagi's saypha MagIQ™ and structured evaluation processes [2][3] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5][9] - It's a Secret Med Spa specializes in advanced aesthetic treatments, being the largest provider of neurotoxins and dermal fillers in Texas and the Southwestern U.S., with 15 high-end locations [6][9] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8]

Core Insights - Aesthetic Record has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on the integration of technology and real-world data to enhance aesthetic practices across the U.S. [1][4] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare, with over 35 years of experience and a focus on addressing various skin concerns [6]. - Aesthetic Record is the leading Electronic Medical Records (EMR) and Practice Management platform specifically designed for the medical aesthetics industry, serving thousands of practices [7][8]. Partnership Details - The partnership aims to leverage Aesthetic Record's technology to capture real-world data, enhancing the launch of Obagi's new injectable, saypha MagIQ™ [2][4]. - The ALOHA Real-World Program will provide Aesthetic Record users with hands-on experience with Obagi products, aiming to improve patient satisfaction and provider relationships [2][3]. Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]. - Aesthetic Record's platform offers integrated tools for efficient charting, compliance monitoring, and performance tracking, which are essential for high-volume aesthetic practices [2][8]. Industry Impact - Initial findings from the partnership will be presented at the Aesthetic Next conference, showcasing the benefits of the new protocols and products within the Aesthetic Record ecosystem [3]. - The collaboration is positioned to advance the aesthetics industry by combining innovative injectables with streamlined technology, ultimately aiming for better patient outcomes [2].

Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]

Core Insights - Next Health has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on personalized wellness and innovative aesthetic treatments [1] - The collaboration aims to conduct a structured assessment of Obagi's saypha MagIQ™ filler, leveraging Next Health's expertise in holistic protocols and patient-centric education [2] Company Overview - Obagi Medical is recognized for its advanced skincare solutions, with over 35 years of experience, and is the fastest-growing professional skincare brand in the U.S. as of 2024 [6][10] - Next Health, founded in 2016, specializes in health optimization and longevity, offering services like IV therapy and hormone optimization through a network of wellness centers [7] Program Details - The ALOHA Program evaluates clinical efficacy and patient experience, aiming to enhance satisfaction and loyalty through integrated Obagi protocols [3] - Standardized data will be collected across Next Health locations, with initial findings to be shared at leadership meetings and major industry conferences [3] Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi saypha MagIQ™ across Alpha's network, focusing on generating real-world evidence of the product's integration into clinical environments [2][3] - The program aims to assess both clinical performance and patient experience, with standardized data collection across participating practices, and initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi saypha ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the launch partner for its ALOHA Program, focusing on the integration of clinical evidence into everyday practice [1][2] Company Overview - Obagi Medical is recognized for its innovative physician-dispensed skincare solutions and has over 35 years of experience in the industry, particularly in treating skin concerns like hyperpigmentation and premature aging [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, emphasizing a collaborative practice model to enhance patient care [7] Program Details - The ALOHA Program aims to generate real-world data to validate the safety and efficacy of Obagi's products, specifically the saypha MagIQ injectable, through hands-on experience and structured evaluations [2][3] - Initial findings from the ALOHA Program will be presented at the annual Platinum Summit in September, showcasing the benefits of the new product within the Platinum network [4] Strategic Intent - The partnership with Platinum signifies Obagi's commitment to launching new injectables based on robust clinical evidence and integrated patient outcomes, aligning with the company's innovative approach to product development [5]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the first partner for its ALOHA Program, emphasizing a commitment to clinical evidence and practice dissemination [1][5] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare and aesthetic solutions, part of Waldencast plc, with over 35 years of experience in advanced skincare [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, focusing on exceptional dermatology practices [7] - Waldencast plc aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to generate real-world data to translate clinical safety and efficacy from FDA trials into everyday practice [2] - The ALOHA Real-World Program will provide hands-on experience with Obagi saypha MagIQ, enhancing patient satisfaction and provider relationships [3] - Initial findings from the program will be presented at the annual Platinum Summit and key industry conferences to showcase the product's real-world impact [4] Product Information - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed for natural-looking results and high performance [5]

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]

Core Insights - Waldencast plc has received FDA approval for Obagi saypha MagIQ™ injectable hyaluronic acid gel, marking its entry into the U.S. HA dermal filler market and aiming to double Obagi Medical's addressable market to approximately $4.2 billion by 2029 [1][2] Company Overview - Waldencast aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, with a focus on operational scale and market responsiveness [8] - Obagi Medical is recognized for its advanced skincare line with over 35 years of experience, initially known for treating hyperpigmentation [9] - Croma-Pharma GmbH, a partner in developing Obagi saypha MagIQ™, has over 40 years of expertise in HA-based treatments and has produced more than 110 million syringes [4][10] Product Details - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix, providing natural-looking results with high HA content and consistent gel distribution [3] - The product is expected to set a new standard in HA dermal fillers in the U.S., with a strong safety profile and proven innovation [2][5] Market Strategy - The launch of Obagi saypha MagIQ™ is planned for 2026, leveraging Obagi Medical's established network of practices and aesthetic professionals to enhance value for providers and patients [2][5] - The U.S. Nasolabial Fold pivotal study for Obagi saypha MagIQ™ included 270 patients and demonstrated non-inferiority to the control with similar safety profiles [5][6]